Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.44 |
| ▸ | USP2 | O75604 | 3/20 | 0.44 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 5/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21886863 | 0.81 | PDE3A (0.44) | ALDH1A1KDM4EUSP2MEN1KMT2A | |
| SCHEMBL10757785 | 0.79 | ALDH1A1 (0.46) | ALDH1A1KDM4EUSP2PRKCZMEN1 | |
| SCHEMBL31503799 | 0.78 | KDM4E (0.44) | ALDH1A1KDM4EUSP2PRKCZMEN1 | |
| SCHEMBL21563533 | 0.78 | ALDH1A1 (0.44) | ALDH1A1KDM4EUSP2PRKCZMEN1 | |
| SCHEMBL31432595 | 0.78 | EPAS1 (0.40) | ALDH1A1KDM4EUSP2PRKCZMEN1 | |
| SCHEMBL15819818 | 0.74 | ALDH1A1 (0.44) | ALDH1A1KDM4EUSP2PRKCZMEN1 | |
| SCHEMBL6385563 | 0.74 | ADORA1 (0.38) | ALDH1A1KDM4EUSP2MEN1KMT2A | |
| SCHEMBL19877832 | 0.74 | KDM4E (0.44) | ALDH1A1KDM4EUSP2PRKCZMEN1 | |
| SCHEMBL17276035 | 0.74 | MAPT (0.47) | ALDH1A1MEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL620373 | 0.73 | ALDH1A1 (0.54) | ALDH1A1KDM4EUSP2PRKCZMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4523755-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | F. Hoffmann-La Roche AG (CH) | 2025-03-19 | — | — | EP | disclosed |
| EP-4360713-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN LA ROCHE (CH) | 2024-10-30 | — | — | EP | disclosed |
| CN-118255772-A | Quinazoline derivatives as antitumor agents | 苏州赞荣医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| EP-4360713-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | F. Hoffmann-La Roche AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| EP-3853220-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN LA ROCHE (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-20230293533-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293533-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293533-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2023-09-21 | — | — | US | disclosed |
| US-11723908-B2 | Quinazoline derivatives as antitumor agents | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2023-08-15 | — | — | US | disclosed |
| US-11723908-B2 | Quinazoline derivatives as antitumor agents | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2023-08-15 | — | — | US | disclosed |
| US-11723908-B2 | Quinazoline derivatives as antitumor agents | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2023-08-15 | — | — | US | disclosed |
| US-20210386742-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2021-12-16 | — | — | US | disclosed |
| US-20210386742-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2021-12-16 | — | — | US | disclosed |
| EP-3853220-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | Suzhou Zanrong Pharma Limited (CN) | 2021-07-28 | — | — | EP | disclosed |
| CN-112654612-A | Quinazoline derivatives as antitumor agents | 苏州赞荣医药科技有限公司 | 2021-04-13 | — | — | CN | disclosed |
| WO-2020057511-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2020-03-26 | — | — | WO | disclosed |
| WO-2020057511-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210386742-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ABL1, TP53, JAK1 | ALDH1A1 3405/4885KDM4E 3671/4885USP2 3574/4885 |
| US-11723908-B2 | Quinazoline derivatives as antitumor agents | ABL1, TP53, JAK1 | ALDH1A1 3405/4885KDM4E 3671/4885USP2 3574/4885 |
| US-20230293533-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ABL1, TP53, JAK1 | ALDH1A1 3405/4885KDM4E 3671/4885USP2 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.